ADME studies and preliminary safety pharmacology of LDT5, a lead compound for the treatment of benign prostatic hyperplasia

ADME studies and preliminary safety pharmacology of LDT5, a lead compound for the treatment of benign prostatic hyperplasia

This study aimed to estimate the absorption, distribution, metabolism and excretion (ADME) properties and safety of LDT5, a lead compound for oral treatment of benign prostatic hyperplasia that has previously been characterized as a multi-target antagonist of α1A-, α1D-adrenoceptors and 5-HT1A recep...

Full description

Bibliographic Details
Main Authors: F. Noël, J.B. Nascimento-Viana, L.A.S. Romeiro, R.O. Silva, L.F.N. Lemes, A.S. Oliveira, T.B.S. Giorno, P.D. Fernandes, C.L.M. Silva
Format: Article
Language:English
Published: Associação Brasileira de Divulgação Científica
Series:Brazilian Journal of Medical and Biological Research
Subjects:
Benign prostatic hyperplasia
ADME
Safety
Permeability
CYP
Preclinical development
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016001200603&lng=en&tlng=en

Similar Items

Similar Items